Clonazepam

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Clonazepam, sold under the brand name Klonopin among others, is a benzodiazepine tranquiliser. It binds to GABAA receptors and increases the effect of the neurotransmitter GABA.[1]

Uses[edit | edit source]

It is used to treat seizures,[2][3] anxiety</ref>[4] and panic disorders,[2][5] movement problems such as akathisia,[5] bruxism[6] or restless legs syndrome,[7] muscle problems[3] and some sleep disorders.[8][9] Several ME/CFS specialists employ clonazepam in their treatment protocols for a variety of uses.[10]

It is usually taken orally and begins having an effect within an hour, lasting between six and twelve hours.[11] It can cause dependence or addiction, and tolerance in long-term use, and withdrawal symptoms are common.[12] Dependence occurs in one-third of people who take clonazepam for longer than four weeks.[1]

ME/CFS[edit | edit source]

Clonazepam is a medication suggestion in the Canadian Consensus Criteria for ME/CFS to help with insomnia, as a muscle relaxant, and for anxiety.[13]:52

Low dose benzodiazepines such as clonazepam are suggested for crashes caused by sensory overload (too much sensory input) according to the International Consensus Criteria.[14]

Risks and safety[edit | edit source]

Clonazepam is highly addictive.[13]:52 Side effects are the same as for other benzodiazepines, and similar to central nervous system depressant drugs; including drowsiness, lack of coordination and ataxia.

Clonazepam and doxepin are often used together to improve sleep duration, and work within 1-2hrs.[13]:52

Clinicans[edit | edit source]

Costs and availability[edit | edit source]

Clonazepam is available in most countries with a prescription. It is available as a generic medication and is generally very inexpensive. Availability may be very restricted due to the risk of addiction and substance misuse.

Dosage[edit | edit source]

For ME/CFS patients a dose of 0.5-2.0 mg per night at bedtime is recommended.[13]:52

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]

  1. 1.0 1.1 Riss, J.; Cloyd, J.; Gates, J.; Collins, S. (August 2008), "Benzodiazepines in epilepsy: pharmacology and pharmacokinetics." (PDF), Acta Neurol Scand, 118 (2): 69–86, doi:10.1111/j.1600-0404.2008.01004.x, PMID 18384456
  2. 2.0 2.1 MedlinePlus – Clonazepam
  3. 3.0 3.1 British National Formulary – Clonazepam
  4. "Clonazepam". NAMI. March 23, 2021.
  5. 5.0 5.1 "Drugs.com – Clonazepam". Drugs.com. March 23, 2021.
  6. Huynh, NT.; Rompré, PH.; Montplaisir, JY.; Manzini, C.; Okura, K.; Lavigne, GJ. (2006), "Comparison of various treatments for sleep bruxism using determinants of number needed to treat and effect size.", Int J Prosthodont, 19 (5): 435–41, PMID 17323720
  7. Trenkwalder, C.; Hening, WA.; Montagna, P.; Oertel, WH.; Allen, RP.; Walters, AS.; Costa, J.; Stiasny-Kolster, K.; Sampaio, C. (December 2008), "Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice" (PDF), Mov Disord, 23 (16): 2267–302, doi:10.1002/mds.22254, PMID 18925578
  8. Ferini-Strambi, L.; Zucconi, M. (September 2000), "REM sleep behavior disorder", Clin Neurophysiol, 111 (Suppl 2): S136–40, doi:10.1016/S1388-2457(00)00414-4, PMID 10996567
  9. Schenck, CH.; Arnulf, I.; Mahowald, MW. (June 2007), "Sleep and Sex: What Can Go Wrong? A Review of the Literature on Sleep Related Disorders and Abnormal Sexual Behaviors and Experiences", Sleep, 30 (6): 683–702, PMID 17580590
  10. Haavisto, Maija (2011), Reviving the Broken Marionette, Lulu.com, pp. 28–29, ISBN 978-1409203353
  11. Cooper, Grant (2007), Therapeutic uses of botulinum toxin, Totowa, N.J.: Humana Press, p. 214, ISBN 9781597452472
  12. Clonazepam, The American Society of Health-System Pharmacists, retrieved December 13, 2016
  13. 13.0 13.1 13.2 13.3 Carruthers, Bruce M.; Jain, Anil Kumar; De Meirleir, Kenny L.; Peterson, Daniel L.; Klimas, Nancy G.; Lerner, A. Martin; Bested, Alison C.; Flor-Henry, Pierre; Joshi, Pradip; Powles, AC Peter; Sherkey, Jeffrey A.; van de Sande, Marjorie I. (2003), "Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Clinical Working Case Definition, Diagnostic and Treatment Protocols" (PDF), Journal of Chronic Fatigue Syndrome, 11 (2): 7–115, doi:10.1300/J092v11n01_02
  14. Carruthers, BM; van de Sande, MI; De Meirleir, KL; Klimas, NG; Broderick, G; Mitchell, T; Staines, D; Powles, ACP; Speight, N; Vallings, R; Bateman, L; Bell, DS; Carlo-Stella, N; Chia, J; Darragh, A; Gerken, A; Jo, D; Lewis, DP; Light, AR; Light, KC; Marshall-Gradisnik, S; McLaren-Howard, J; Mena, I; Miwa, K; Murovska, M; Stevens, SR (2012), Myalgic encephalomyelitis: Adult & Paediatric: International Consensus Primer for Medical Practitioners (PDF), ISBN 978-0-9739335-3-6